Emdogain has been used clinically for periodontal regeneration, although the underlying molecular mechanisms are not clear at present. In this study, we hypothesized that Emdogain stimulated degradation of type I collagen via osteoblasts. We showed that Emdogain enhanced cell-mediated degradation of type I collagen in an MMP-dependent manner. Although MG-63 cells spontaneously produced a zymogen form of MMP-1, treatment with Emdogain significantly induced the generation of the active form of this enzyme. We demonstrated that MMP-3 was produced from MG63 cells in response to Emdogain in a MEK1/2-dependent manner. Concomitantly, blocking of MEK1/2 activation by U0126 significantly inhibited the generation of the active form of MMP-1 without affecting the total production of this collagenase. These results suggest that Emdogain facilitates tissue regeneration through the activation of the collagenase, MMP-1, that degrades matrix proteins in bone tissue microenvironments.
Get full access to this article
View all access options for this article.
References
1.
Benbow U, Buttice G, Nagase H, Kurkinen M -1996-. Characterization of the 46-kDa intermediates of matrix metalloproteinase 3 -stromelysin 1- obtained by site-directed mutation of phenylalanine 83. J Biol Chem271:10715–10722.
2.
Boyan BD, Weesner TC, Lohmann CH, Andreacchio D, Carnes DL, Dean DD, et al. -2000-. Porcine fetal enamel matrix derivative enhances bone formation induced by demineralized freeze dried bone allograft in vivo. J Periodontol71:1278–1286.
3.
Cochran DL, Jones A, Heijl L, Mellonig JT, Schoolfield J, King GN -2003-. Periodontal regeneration with a combination of enamel matrix proteins and autogenous bone grafting. J Periodontol74:1269–1281.
4.
Fujisaki K, Tanabe N, Suzuki N, Mitsui N, Oka H, Ito K, et al. -2006-. The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells. Life Sci78:1975–1982.
5.
Gestrelius S, Andersson C, Lidström D, Hammarström L, Somerman M -1997-. In vitro studies on periodontal ligament cells and enamel matrix derivative. J Clin Periodontol24:685–692.
6.
Goda S, Inoue H, Umehara H, Miyaji M, Nagano Y, Harakawa N, et al. -2006-. Matrix metalloproteinase-1 produced by human CXCL12-stimulated natural killer cells. Am J Pathol169:445–458.
7.
Hammarström L, Heijl L, Gestrelius S -1997-. Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. J Clin Periodontol24:669–677.
8.
Heijl L -1997-. Periodontal regeneration with enamel matrix derivative in one human experimental defect. A case report. J Clin Periodontol24:693–696.
9.
Heijl L, Heden G, Svardström G, Ostgren A -1997-. Enamel matrix derivative -EMDOGAIN- in the treatment of intrabony periodontal defects. J Clin Periodontol24:705–714.
10.
Hoberg M, Rudert M, Pap T, Klein G, Gay S, Aicher WK -2007-. Attachment to laminin-111 facilitates transforming growth factor beta-induced expression of matrix metalloproteinase-3 in synovial fibroblasts. Ann Rheum Dis66:446–451.
11.
Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, et al. -1999-. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell99:81–92.
12.
Itoh N, Kasai H, Ariyoshi W, Harada E, Yokota M, Nishihara T -2006-. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative. J Periodontal Res41:273–279.
13.
Kajanne R, Miettinen P, Mehlem A, Leivonen SK, Birrer M, Foschi M, et al. -2007-. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol212:489–497.
14.
Krane SM -1995-. Is collagenase -matrix metalloproteinase-1- necessary for bone and other connective tissue remodeling? Clin Orthop Relat Res313:47–53.
15.
Matsuda N, Horikawa M, Watanabe M, Kitagawa S, Kudo Y, Takata T -2002-. Possible involvement of extracellular signal-regulated kinases 1/2 in mitogenic response of periodontal ligament cells to enamel matrix derivative. Eur J Oral Sci110:439–444.
16.
McCawley LJ, Matrisian LM -2001-. Matrix metalloproteinases: they’re not just for matrix anymore! Curr Opin Cell Biol13:534–540.
17.
McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM -2002-. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood100:1160–1167.
Nagase H, Suzuki K, Morodomi T, Enghild JJ, Salvesen G -1992-. Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix Suppl1:237–244.
20.
Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y -1997-. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem272:2446–2451.
21.
Okuda K, Miyazaki A, Momose M, Murata M, Nomura T, Kubota T, et al. -2001-. Levels of tissue inhibitor of metalloproteinases-1 and matrix metalloproteinases-1 and -8 in gingival crevicular fluid following treatment with enamel matrix derivative -EMDOGAIN-. J Periodontal Res36:309–316.
22.
Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, et al. -2001-. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol69:851–859.
23.
Sasaki K, Takagi M, Konttinen YT, Sasaki A, Tamaki Y, Ogino T, et al. -2007-. Upregulation of matrix metalloproteinase -MMP--1 and its activator MMP-3 of human osteoblast by uniaxial cyclic stimulation. J Biomed Mater Res B Appl Biomater80:491–498.
24.
Sculean A, Blaes A, Arweiler N, Reich E, Donos N, Brecx M -2001-. The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins. J Periodontol72:190–195.
25.
Seiki M -2003-. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett194:1–11.
26.
Suzuki S, Nagano T, Yamakoshi Y, Gomi K, Arai T, Fukae M, et al. -2005-. Enamel matrix derivative gel stimulates signal transduction of BMP and TGF-{beta}. J Dent Res84:510–514.
27.
Takiguchi T, Kobayashi M, Suzuki R, Yamaguchi A, Isatsu K, Nishihara T, et al. -1998-. Recombinant human bone morphogenetic protein-2 stimulates osteoblast differentiation and suppresses matrix metalloproteinase-1 production in human bone cells isolated from mandibulae. J Periodontal Res33:476–485.
28.
Tanimura S, Asato K, Fujishiro SH, Kohno M -2003-. Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem Biophys Res Commun304:801–806.
29.
Visse R, Nagase H -2003-. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res92:827–839.
30.
Vu TH, Werb Z -2000-. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev14:2123–2133.
31.
Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, et al. -1998-. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell93:411–422.
32.
Wang EA, Rosen V, D’Alessandro JS, Bauduy M, Cordes P, Harada T, et al. -1990-. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA87:2220–2224.
33.
Yoneda S, Itoh D, Kuroda S, Kondo H, Umezawa A, Ohya K, et al. -2003-. The effects of enamel matrix derivative -EMD- on osteoblastic cells in culture and bone regeneration in a rat skull defect. J Periodontal Res38:333–342.
34.
Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, et al. -2000-. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA97:4052–4057.
